| Metric | Value ($ M) | vs Q2 FY26 |
|---|---|---|
| Revenue | 1.49 | 10.8% |
| Total Income | 1.49 | 10.8% |
| Expenditure | 13.23 | 60.9% |
| PBT | -12.03 | 57.5% |
| Net Profit | -8.86 | 58.3% |
| OPM | — | |
| NPM | — | |
| EPS | -0.34 | 64.2% |
Citius Pharmaceuticals Reports Fiscal Third Quarter 2026 Financial Results
15 Aug 2026 · 15 Aug, 2:18 am
Summary
Citius Pharmaceuticals reported Q3 FY26 revenue of $1.5 million, marking a significant increase from zero revenue in the prior year quarter, driven by the commercial sales of LYMPHIR®. For the first nine months of fiscal 2026, revenue totaled $7.1 million. The company achieved a gross profit of $1.0 million in the quarter with a 67% gross margin and ended with $17.0 million in cash. The net loss applicable to common stockholders for the quarter was $8.9 million, or $(0.34) per share. Management highlighted the continued momentum of the LYMPHIR launch and positive clinical data for its potential beyond cutaneous T-cell lymphoma.
Key Highlights
- 1
Citius Pharmaceuticals reported revenue of $1.5 million for the fiscal third quarter ended June 30, 2026, compared to no revenue in the prior year period.
- 2
For the first nine months of fiscal 2026, revenue reached $7.1 million from commercial sales of LYMPHIR®.
- 3
Gross profit for the fiscal third quarter was $1.0 million, representing a gross margin of approximately 67%.
- 4
The company ended the quarter with $17.0 million in cash and cash equivalents as of June 30, 2026.
- 5
Net loss applicable to common stockholders was $8.9 million, or $(0.34) per share, for the three months ended June 30, 2026.
- 6
Phase 1 data presented at ASTCT® & CIBMTR® Tandem Meetings showed an 86% objective response rate for LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL.
Management Comments
Leonard Mazur
The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR’s differentiated clinical profile. Following the quarter end, we completed the nationwide deployment of Citius Oncology’s expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR’s success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures. We also continued to advance LYMPHIR’s longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings, showed an 86% objective response rate, including 57% complete response, with no dose-limiting toxicities observed. These positive signals point to LYMPHIR’s potential beyond cutaneous T-cell lymphoma. As we scale, we remain focused on disciplined execution and building the long-term sustainable value of LYMPHIR.
Informational and educational content only. Not investment advice.